Home/ Stocks/ APLS

Apellis Pharmaceuticals, Inc. Common Stock

APLS XNAS

$40.27 +23.17 (+135.58%) ▲ 15-min delayed

Open

$40.40

High

$40.45

Low

$40.25

Volume

73.46M

Market Cap

$2.18B

About Apellis Pharmaceuticals, Inc. Common Stock

Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).

Sector: PHARMACEUTICAL PREPARATIONS Employees: 733 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2025	$458.58M	$215.72M	$1.71
Q2 2025	$178.49M	$-42,151,000	$-0.33
Q1 2025	$166.80M	$-92,225,000	$-0.74
FY 2024	$781.37M	$-197,878,000	$-1.60

TickerDaily Coverage

Why Is Apellis Pharmaceuticals, Inc. Common Stock (APLS) Stock Up 136.4% Today?

Market News Alex Chen · 3h ago

Apellis Pharmaceuticals stock exploded 136.4% to $40.39 on Tuesday, March 31, 2026, on massive...

View All Coverage →

Get APLS Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Apellis Pharmaceuticals, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.